Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus

What happened: Moderna shares fell after leaked data for its personalized cancer vaccine, intismeran autogene, developed with Merck, was released ahead of the ESMO Congress. Roche and Hansoh Pharma also announced a licensing deal for antibody-drug conjugates. Key numbers: Moderna closed down more than 17% Thursday; Merck closed down about 2%. Why it matters: TD Cowen's Tyler Van Buren said the distant metastasis results were less exceptional than those for recurrent-free survival. The Roche-Hansoh partnership is the second such deal between the companies in the ADC space. Market: +1.2% today ($103.70), -15.5% YTD, 1.1x vol — as of 23:45 UTC

Moderna shares fell after leaked data for its personalized cancer vaccine, intismeran autogene, developed with Merck, was released ahead of the ESMO Congress. Roche and Hansoh Pharma also announced a licensing deal for antibody-drug conjugates.

TD Cowen's Tyler Van Buren said the distant metastasis results were less exceptional than those for recurrent-free survival. The Roche-Hansoh partnership is the second such deal between the companies in the ADC space. Market: +1.2% today ($103.70), -15.5% YTD, 1.1x vol — as of 23:45 UTC